EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Evotec SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026
$1.42+0.04 (+2.90%)
Close on Oct 19, 2026
Evotec SE revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| D&PD | €528.93M | €611.39M | €672.98M | €702.02M | – | – | – | 67.1% | -13.5% |
| JEB | €259.44M | €185.57M | €108.45M | €49.43M | – | – | – | 32.9% | +39.8% |
| EVT Execute | – | – | €514.54M | €546.72M | €471.05M | €394.09M | €351.37M | – | – |
| EVT Innovate | – | – | €266.88M | €204.73M | €146.98M | €106.83M | €95.07M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | YoY |
|---|---|---|---|---|---|---|---|---|
| JEB | €18.27M | -€16.35M | -€39.39M | -€63.04M | – | – | – | -211.7% |
| D&PD | -€74.48M | -€126.17M | -€8.12M | €83.89M | – | – | – | -41.0% |
| EVT Execute | – | – | -€43.02M | €32.52M | €63.11M | €77.36M | €76.92M | – |
| EVT Innovate | – | – | -€4.49M | -€11.67M | -€22.11M | -€28.81M | -€14.21M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Fee for service and FTE-based research services | €612.93M | €737.39M | €726.93M | €673.44M | €522.19M | €460.59M | €398.58M | 77.7% | -16.9% |
| Licences | €122.35M | €3.13M | €675.00K | €2.39M | €245.00K | €42.00K | €1.90M | 15.5% | +3808.8% |
| Material re-charges to customers | €31.89M | €38.58M | €37.56M | €44.44M | €35.99M | €21.84M | €14.50M | 4.0% | -17.3% |
| Milestone fees | €9.62M | €2.87M | €4.79M | €18.07M | €49.47M | €17.09M | €30.44M | 1.2% | +234.9% |
| Other fees | €300.00K | €544.00K | €2.06M | – | – | – | – | 0.0% | -44.9% |
| Contributions | – | – | – | – | €8.57M | €4.65M | €4.55M | – | – |
| Compound access fees | – | €544.00K | €2.06M | €2.57M | €1.58M | €1.36M | €1.02M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | €431.51M | €445.86M | €459.42M | €407.75M | €329.04M | €247.85M | €195.04M | 54.7% | -3.2% |
| Switzerland | €161.61M | €109.04M | €64.92M | €22.00K | €24.48M | – | – | 20.5% | +48.2% |
| Rest of the world | €77.09M | €82.28M | €95.15M | €126.70M | €73.87M | €77.71M | €82.68M | 9.8% | -6.3% |
| United Kingdom | €61.72M | €92.52M | €86.37M | €115.26M | €104.64M | €93.99M | €77.90M | 7.8% | -33.3% |
| Germany | €25.29M | €32.90M | €34.13M | €58.90M | €46.85M | €44.32M | €27.98M | 3.2% | -23.1% |
| France | €19.86M | €19.91M | €32.01M | €32.27M | €30.59M | €37.06M | €62.83M | 2.5% | -0.3% |
From the segment and revenue-disaggregation notes of Evotec's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.